2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Classical hematology
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Hand-Foot Syndrome
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
155
Dexamethasone
141
Rituximab
85
fludarabine
80
Lenalidomide
72
Cytarabine
70
Bortezomib
65
fludarabine phosphate
63
Gemcitabine
62
venetoclax
55
pomalidomide
53
Etoposide
53
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Pharmacokinetics
×
Clear all
NCT04861181
2025-05-22
NIRAPK
Hospices Civils de Lyon
Phase 4
Terminated
12 enrolled